Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2019 | JULIET: CRS and neurotoxicity in DLBCL

David Maloney • 13 Jun 2019
EHA 2019
Diffuse Large B-Cell Lymphoma Lymphoma
JULIET

A post-hoc analysis of the JULIET trial (NCT02445248) is discussed by David Maloney, MD, PhD, Fred Hutchinson Cancer Research Center, Seattle, WA. The analysis investigated CRS and neurotoxicity in the treatment of adult relapsed or refractory diffuse large B-cell lymphoma (DLBCL) with CAR T-cell therapy. This interview took place at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.

More from David Maloney

Expanding the CAR platform in NHL
David Maloney et al. • 17 Oct 2023
14:23
Highlights from Day 2: addressing challenges in CAR-T therapy for ALL, AML, CLL & more…
David Maloney et al. • 30 Apr 2022
10:21
Advances in CAR-T therapy for lymphoma
Caron Jacobson et al. • 1 May 2022
4:36
Highlights from the immunotherapy in CLL session
David Maloney • 20 Sep 2021

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals